A phase 2 clinical trial (NCT02723994) led by the Children’s Oncology Group is currently assessing ruxolitinib in combination with chemotherapy for the treatment of ALL patients harboring CRLF2 and/or JAK pathway alterations (Senkevitch and Durum, 2017). The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.